On Wednesday, Royalty Pharma plc (RPRX) stock saw a decline, ending the day at $28.24 which represents a decrease of $-0.14 or -0.49% from the prior close of $28.38. The stock opened at $28.23 and ...

Arrowhead's plozasiran shows promising Phase 3 data for FCS, with potential blockbuster status, but faces competition. Learn ...

Gilead Sciences is granting licenses to six companies to produce lenacapavir for pre-exposure prophylaxis, as well as for ...

With a recently acquired FDA nod for its Halozyme Therapeutics-partnered Vyvgat Hytrulo, argenx is looking to take Halozyme’s ...

Gilead Sciences, Inc. has announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six ...

Enara Bio has raised $32.5m in a Series B financing round to advance its platform shining a light on cancer-specific antigens ...

Health care stocks underperformed the broader market in 2023, with many companies falling short of their profit targets, and ...

Emcure Pharmaceuticals on Thursday said it has signed a royalty-free voluntary licensing agreement with Gilead Sciences ...

Gilead's licensing agreement for lenacapavir a move to preserve its monopoly, alleges TWN: Our Bureau, New Delhi Thursday, October 3, 2024, 12:20 Hrs [IST] Third World Network (TW ...

Gilead Sciences signs voluntary licensing agreement with six pharma firms to produce generic lenacapavir: Our Bureau, New Delhi Thursday, October 3, 2024, 11:30 Hrs [IST] US-based ...

The U.S.-based drugmaker also plans to provide the companies branded version of the drug, lenacapavir, in 18 countries, such ...

Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV ...